Implications of inhibition of Rev1 interaction with Y family DNA polymerases for cisplatin chemotherapy
Open Access
- 12 August 2021
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 35 (17-18), 1256-1270
- https://doi.org/10.1101/gad.348662.121
Abstract
Chemotherapy with cisplatin becomes limiting due to toxicity and secondary malignancies. In principle, therapeutics could be improved by targeting translesion synthesis (TLS) polymerases (Pols) that promote replication through intrastrand cross-links, the major cisplatin-induced DNA adduct. However, to specifically target malignancies with minimal adverse effects on normal cells, a good understanding of TLS mechanisms in normal versus cancer cells is paramount. We show that in normal cells, TLS through cisplatin intrastrand cross-links is promoted by Polη- or Polι-dependent pathways, both of which require Rev1 as a scaffolding component. In contrast, cancer cells require Rev1-Polζ. Our findings that a recently identified Rev1 inhibitor, JH-RE-06, purported to specifically disrupt Rev1 interaction with Polζ to block TLS through cisplatin adducts in cancer cells, abrogates Rev1's ability to function with Y family Pols as well, implying that by inactivating Rev1-dependent TLS in normal cells, this inhibitor will exacerbate the toxicity and tumorigenicity of chemotherapeutics with cisplatin.Keywords
Funding Information
- National Institutes of Health (R01 GM126087)
This publication has 45 references indexed in Scilit:
- Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapyNature Structural & Molecular Biology, 2012
- Requirement of Rad18 protein for replication through DNA lesions in mouse and human cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatinProceedings of the National Academy of Sciences of the United States of America, 2012
- Error-prone translesion synthesis mediates acquired chemoresistanceProceedings of the National Academy of Sciences of the United States of America, 2010
- Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapyProceedings of the National Academy of Sciences of the United States of America, 2010
- Highly error-free role of DNA polymerase η in the replicative bypass of UV-induced pyrimidine dimers in mouse and human cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Recognition and processing of cisplatin- and oxaliplatin-DNA adductsCritical Reviews in Oncology/Hematology, 2005
- NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) d(GpG) Intrastrand Cross-Link, the Major Adduct of the Anticancer Drug CisplatinBiochemistry, 1998